Logo of MD Anderson Cancer Center from X
Oct 24, 2023, 13:44
MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone – MD Anderson Cancer Center
Quoting
“MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone.
“These findings showcase, for the first time, the potential of combining immunotherapy with a PARP inhibitor to deliver significant clinical improvements for these patients,” says lead investigator Shannon Westin.”
For more details click here.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 6, 2025, 16:00
Jan 6, 2025, 15:59
Jan 6, 2025, 15:49
Jan 6, 2025, 15:47
Jan 6, 2025, 15:04
Jan 6, 2025, 14:59
Jan 6, 2025, 14:52